Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A known ✓ | P37088 | 11/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | HPGD | P15428 | 7/20 | 0.54 |
| ▸ | GLA | P06280 | 7/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.54 |
| ▸ | PLAU | P00749 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | GMNN | O75496 | 3/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiloride SCHEMBL1487484 | 1.00 | SCNN1A (0.56) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL29129215 | 0.98 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL41233 | 0.98 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL15517241 | 0.97 | SCNN1A (0.58) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL27562 | 0.97 | SCNN1A (0.58) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL41234 | 0.95 | SCNN1A (0.55) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL1441814 | 0.95 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL17986365 | 0.95 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL21524891 | 0.95 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL3253482 | 0.95 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133679-A1 | COMPOUNDS AND COMPOSITION FOR DNA PROTECTION | ASSOCIAÇÃO PARA DESENVOLVIMENTO DO CENTRO ACADÉMICO DE INVESTIGAÇÃO E FORMAÇÃO BIOMÉDICA DO ALGARVE, AD-ABC (PT) | 2025-06-26 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024102612-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS FOR MODULATING GLUCOSE TRANSPORT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | claimed |
| US-20100015127-A1 | TREATMENT FOR DEMYELINATING DISEASE | MEDICAL RESEARCH COUNCIL | 2010-01-21 | — | — | US | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| EP-2043650-A2 | TREATMENT FOR DEMYELINATING DISEASE | Medical Research Council (GB) | 2009-04-08 | — | — | EP | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| WO-2008007131-A2 | TREATMENT FOR DEMYELINATING DISEASE | MEDICAL RESEARCH COUNCIL (GB) | 2008-01-17 | — | — | WO | claimed |
| WO-2004000331-A1 | ORGAN ARREST, PROTECTION, PRESERVATION AND RECOVERY | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2003-12-31 | — | — | WO | claimed |
| US-4178374-A | SUBSTITUTED 1,2,5-THIADIAZOLE B-ADRENERGIC BLOCKING AGENT, PYRAZINE AND/OR THIAZIDE DIURETIC, TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 1979-12-11 | — | — | US | claimed |
| CN-121570607-A | EGFR endocytosis-mediated targeted protein degradation system and application thereof | 西湖大学 | 2026-02-27 | — | — | CN | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2025133679-A1 | COMPOUNDS AND COMPOSITION FOR DNA PROTECTION | ASSOCIAÇÃO PARA DESENVOLVIMENTO DO CENTRO ACADÉMICO DE INVESTIGAÇÃO E FORMAÇÃO BIOMÉDICA DO ALGARVE, AD-ABC (PT) | 2025-06-26 | — | — | WO | disclosed |
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-4237144-A | DIURETIC-SALURETIC, URICOSURIC, HYPOTENSIVE | MERCK & CO., INC. (US) | 1980-12-02 | — | — | US | disclosed |
| US-4190655-A | DIURETICS, HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1980-02-26 | — | — | US | disclosed |
| US-4178374-A | SUBSTITUTED 1,2,5-THIADIAZOLE B-ADRENERGIC BLOCKING AGENT, PYRAZINE AND/OR THIAZIDE DIURETIC, TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 1979-12-11 | — | — | US | disclosed |
| US-4163794-A | DIURETICS, URICOSURIC, HYPOTENSIVE | MERCK & CO., INC. (US) | 1979-08-07 | — | — | US | disclosed |
| US-4087542-A | DIURETICS, SALURETICS, URICOSURICS, HYPOTENSIVES, ANTIEDEMIC AGENTS | MERCK & CO., INC. (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | SCNN1A 2168/4885ALDH1A1 1909/4885KDM4E 1147/4885 |
| US-20100015127-A1 | TREATMENT FOR DEMYELINATING DISEASE | ASIC1, ASIC3, TRPM2 | SCNN1A 44/4885ALDH1A1 3425/4885KDM4E 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.